Wegovy's heart benefits due to more than weight loss: Novo Nordisk
Novo Nordisk presented groundbreaking data at the American Heart Association meeting, shedding light on the multifaceted cardiovascular benefits of its obesity treatment, Wegovy. Contrary to conventional understanding that the drug's efficacy is solely linked to weight loss, findings from the Select trial unveiled broader positive impacts on heart health.
Earlier data from the trial, released in August, had already shown that Wegovy, scientifically known as semaglutide, reduced the incidence of heart attacks, strokes, and death from heart disease by 20%, in addition to facilitating an average weight loss of 15% in patients.
For more news & updates, check out the link given below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.